FLT3 and acute myeloid leukemia: In a phase 1 study of 50 patients with R/R AML, including 28 with FLT3-ITD and 6 with both ITD and TKD mutations, sorafenib monotherapy achieved complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) in 5 patients, with an additional 17 showing significant reduction in bone marrow or peripheral blood blasts [43].